Takeda to Divest its Consumer Health Unit to Blackstone for $2.3B in Japan


  • Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021
  • The portfolio to be divested includes OTC medicines and health products along with its lead product in the region, Alinamin. Blackstone plans to develop the business together with current TCHC management and continue to employ its employees
  • The divestiture allows Takeda to refocus on its five key business areas and reduce debt after its $59 billion acquisition of Shire

Click here ­to­ read full press release/ article | Ref: Takeda | Image: StraitTimes